GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Milei Threatens Falkland Oil Firms With Sanctions 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Add as a preferred source on Google
CAMBRIDGE, Mass., Feb. 26, 2018 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced its presentation at the upcoming investor conference:
- Cowen 38th Annual Health Care Conference, Boston, MA
Date: Monday, March 12, 2018
Time: 11:20 a.m. EST
Presenter: Jane Henderson, chief financial officer and senior vice president of corporate development
Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, with AbbVie, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.
Investor Relations: Matt Osborne Vice President of Investor Relations & Corporate Communications 857-259-5353 [email protected] Media: Katie Engleman Pure Communications, Inc. 910-509-3977 [email protected]
